08:14 AM EDT, 08/28/2024 (MT Newswires) -- Palatin Technologies ( PTN ) said Wednesday the Food and Drug Administration has confirmed protocols and endpoints for signs and symptoms of the remaining phase 3 clinical trial program for PL9643 eye drops in treating dry eye disease.

The remaining phase 3 clinical trial program consists of two phase 3 studies that will evaluate both signs and symptoms of dry eye disease.

Palatin ( PTN ) said patient enrollment in the trials is expected to start in Q4.

The new drug application submission is expected for H1 2026 if the recruitment goals are met and the trial results are successful, the company said.

Price: 1.5479, Change: +0.06, Percent Change: +3.89